Kiyong Na1,2, Hyun-Soo Kim2, Hyo Sup Shim2, Jong Hee Chang3, Seok-Gu Kang3, Se Hoon Kim4. 1. Department of Pathology, Kyung Hee University School of Medicine, Seoul, Republic of Korea. 2. Department of Pathology, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea. 3. Department of Neurosurgery, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea. 4. Department of Pathology, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea. paxco@yuhs.ac.
Abstract
PURPOSE: The TruSight Tumor 170 (TST-170) panel consists of a DNA workflow for the identification of single-nucleotide variants, small insertions and deletions, and copy number variation, as well as a panel of 55 genes for a RNA workflow for the identification of splice variants and gene fusions. To date, the application of TST-170 in diffuse gliomas (DGs) has not been described. METHODS: We analyzed 135 samples of DG, which were diagnosed by WHO criteria based on histological features and conventional molecular tests including immunostaining, 1p/19q FISH, and analysis of MGMT methylation and TERT promoter mutation. RESULTS: A total of 135 cases consisted of 38 IDH-mutant [17 astrocytoma (AC), 13 oligodendroglioma (OD) and eight glioblastoma (GBM)], 87 IDH-wildtype (six AC, three OD and 78 GBM), and 10 diffuse midline glioma, H3K27M-mutant. DNA analysis enabled the detection of all mutations identified in these samples by conventional techniques, and the results were highly comparable to the known mutations in each subtype. RNA analysis detected four fusion genes including PTPRZ1-MET, FGFR3-TACC3, FAM131B-BRAF, and RET-CCDC6 and one splicing variant (EGFR vIII mutant). Clustered copy number loss in 1p and 19q loci genes were detected in 1p/19q-codeleted OD. CONCLUSIONS: The application of TST-170 panel based NGS in clinical and laboratory setting is expected to improve diagnostic accuracy and prognostication. Most benefits are expected in IDH-wildtype DG, a group of genetically heterogenous tumors harboring DNA sequence changes, copy number alterations, and fusions in a large number of oncogenes and tumor suppressor genes.
PURPOSE: The TruSight Tumor 170 (TST-170) panel consists of a DNA workflow for the identification of single-nucleotide variants, small insertions and deletions, and copy number variation, as well as a panel of 55 genes for a RNA workflow for the identification of splice variants and gene fusions. To date, the application of TST-170 in diffuse gliomas (DGs) has not been described. METHODS: We analyzed 135 samples of DG, which were diagnosed by WHO criteria based on histological features and conventional molecular tests including immunostaining, 1p/19q FISH, and analysis of MGMT methylation and TERT promoter mutation. RESULTS: A total of 135 cases consisted of 38 IDH-mutant [17 astrocytoma (AC), 13 oligodendroglioma (OD) and eight glioblastoma (GBM)], 87 IDH-wildtype (six AC, three OD and 78 GBM), and 10 diffuse midline glioma, H3K27M-mutant. DNA analysis enabled the detection of all mutations identified in these samples by conventional techniques, and the results were highly comparable to the known mutations in each subtype. RNA analysis detected four fusion genes including PTPRZ1-MET, FGFR3-TACC3, FAM131B-BRAF, and RET-CCDC6 and one splicing variant (EGFR vIII mutant). Clustered copy number loss in 1p and 19q loci genes were detected in 1p/19q-codeleted OD. CONCLUSIONS: The application of TST-170 panel based NGS in clinical and laboratory setting is expected to improve diagnostic accuracy and prognostication. Most benefits are expected in IDH-wildtype DG, a group of genetically heterogenous tumors harboring DNA sequence changes, copy number alterations, and fusions in a large number of oncogenes and tumor suppressor genes.
Authors: A Woehrer; P Sander; C Haberler; S Kern; H Maier; M Preusser; C Hartmann; J M Kros; J A Hainfellner Journal: Clin Neuropathol Date: 2011 Mar-Apr Impact factor: 1.368
Authors: Jayne M Stommel; Alec C Kimmelman; Haoqiang Ying; Roustem Nabioullin; Aditya H Ponugoti; Ruprecht Wiedemeyer; Alexander H Stegh; James E Bradner; Keith L Ligon; Cameron Brennan; Lynda Chin; Ronald A DePinho Journal: Science Date: 2007-09-13 Impact factor: 47.728
Authors: Christian Hartmann; Jochen Meyer; Jörg Balss; David Capper; Wolf Mueller; Arne Christians; Jörg Felsberg; Marietta Wolter; Christian Mawrin; Wolfgang Wick; Michael Weller; Christel Herold-Mende; Andreas Unterberg; Judith W M Jeuken; Peter Wesseling; Guido Reifenberger; Andreas von Deimling Journal: Acta Neuropathol Date: 2009-06-25 Impact factor: 17.088
Authors: Jinghui Zhang; Gang Wu; Claudia P Miller; Ruth G Tatevossian; James D Dalton; Bo Tang; Wilda Orisme; Chandanamali Punchihewa; Matthew Parker; Ibrahim Qaddoumi; Fredrick A Boop; Charles Lu; Cyriac Kandoth; Li Ding; Ryan Lee; Robert Huether; Xiang Chen; Erin Hedlund; Panduka Nagahawatte; Michael Rusch; Kristy Boggs; Jinjun Cheng; Jared Becksfort; Jing Ma; Guangchun Song; Yongjin Li; Lei Wei; Jianmin Wang; Sheila Shurtleff; John Easton; David Zhao; Robert S Fulton; Lucinda L Fulton; David J Dooling; Bhavin Vadodaria; Heather L Mulder; Chunlao Tang; Kerri Ochoa; Charles G Mullighan; Amar Gajjar; Richard Kriwacki; Denise Sheer; Richard J Gilbertson; Elaine R Mardis; Richard K Wilson; James R Downing; Suzanne J Baker; David W Ellison Journal: Nat Genet Date: 2013-04-14 Impact factor: 38.330
Authors: A M Zeitlberger; P M Putora; S Hofer; P Schucht; D Migliorini; A F Hottinger; U Roelcke; H Läubli; P Spina; O Bozinov; M Weller; M C Neidert; T Hundsberger Journal: J Neurooncol Date: 2022-04-29 Impact factor: 4.130
Authors: Alexandra McAleenan; Hayley E Jones; Ashleigh Kernohan; Tomos Robinson; Lena Schmidt; Sarah Dawson; Claire Kelly; Emmelyn Spencer Leal; Claire L Faulkner; Abigail Palmer; Christopher Wragg; Sarah Jefferies; Sebastian Brandner; Luke Vale; Julian Pt Higgins; Kathreena M Kurian Journal: Cochrane Database Syst Rev Date: 2022-03-02
Authors: C J Park; K Han; H Kim; S S Ahn; D Choi; Y W Park; J H Chang; S H Kim; S Cha; S-K Lee Journal: AJNR Am J Neuroradiol Date: 2021-01-28 Impact factor: 3.825
Authors: Sebastian Brandner; Alexandra McAleenan; Hayley E Jones; Ashleigh Kernohan; Tomos Robinson; Lena Schmidt; Sarah Dawson; Claire Kelly; Emmelyn Spencer Leal; Claire L Faulkner; Abigail Palmer; Christopher Wragg; Sarah Jefferies; Luke Vale; Julian P T Higgins; Kathreena M Kurian Journal: Neuropathol Appl Neurobiol Date: 2022-03-03 Impact factor: 6.250
Authors: Lan Wang; Anudeep Yekula; Koushik Muralidharan; Julia L Small; Zachary S Rosh; Keiko M Kang; Bob S Carter; Leonora Balaj Journal: Cancers (Basel) Date: 2020-05-13 Impact factor: 6.639